Speakers
Prof. Alice Pik-Shan KONG
Professor, Division of Endocrinology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
Dr. Kong is Professor in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong, and Honorary Consultant at the Prince of Wales Hospital, Hong Kong. Dr. Kong graduated from The Chinese University of Hong Kong and completed her training in General Medicine and Endocrinology at Queen Elizabeth Hospital, Hong Kong. She had her overseas training as postdoctoral fellow under the mentorship of Dr. Robert Henry at the Division of Endocrinology, Department of Medicine at University of California, San Diego, United States between 1998 and 1999. She became a Fellow of the Hong Kong Academy of Medicine in 2000, with accreditation in Advanced Internal Medicine, Endocrinology, Diabetes and Metabolism. She is also a Fellow of the Royal College of Physicians, Glasgow and Edinburgh. She is the chairperson of Specialty Board in Advanced Internal Medicine, Hong Kong College of Physicians since 2017.
Dr. Kong is the Steering Committee Member of Joint Asia Diabetes Evaluation (JADE) program. She is the Council Member of Diabetes Hong Kong and the former Vice President of Hong Kong Association for the Study of Obesity. Other memberships include Hong Kong Society of Endocrinology, Metabolism and Reproduction and American Diabetes Association. Dr. Kong’s research interests are obesity, insulin resistance and diabetes with particular focus on lifestyle factors including sleep and diet in adults and adolescents. She is an invited reviewer for many local and international journals, including Annals of Internal Medicine, Diabetes, Diabetes Care, Clinical Endocrinology, Diabetic Medicine, etc. She is an Associate Editor of Primary Care Diabetes, International Associate Editor of Diabetes Technology and Therapeutics and an editorial board member of Current Diabetes Reports. She has presented at numerous local, regional and international meetings and has published over 230 articles in peer-reviewed journals.
Abstract
Management of People with Diabetes and Cardiovascular Diseases - What's New?
Current guidelines from American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) highlight the compelling need to minimize hypoglycemia in choosing glucose-lowering medication in people with diabetes, particularly in those with established cardiovascular disease (CVD).
For diabetes with established atherosclerotic cardiovascular disease (ASCVD) or those at risk, glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2 i) are recommended independent of glycated haemoglobin (HbA1c) due to the CVD benefits from results of cardiovascular outcomes trials (CVOTs).
In view of the progressive nature of type 2 diabetes (T2D), many patients with T2D may eventually require insulin therapy. Basal insulin is the most convenient initial insulin regimen and long-acting basal insulin analogs may convey a lower hypoglycemic risk compared to human insulin. The combination of basal insulin analogs and GLP-1 RA is an attractive treatment option for T2D with CVD who need insulin therapy. This presentation will review the evidence and guidelines regarding the choice of anti-diabetic regimen in T2D with CVD.